CLINICAL_TRIALS
trial_result
· 2018-05-15
Clinical Trial Update: Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease [Phase 2]
Summary
Phase 2 trial of Restasis X (cyclosporine ophthalmic formulation) for dry eye disease was terminated. Results from the study were posted in May 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Allergan | Conditions: Dry Eye Syndromes | Phase 2 | Status: TERMINATED | Results posted: 2018-05-15